Table II.
Demographic and clinical characteristics of subjects from the Center for Disease Control Vaccine Adverse Events Reporting System reporting psoriasis following COVID-19 vaccination
| Total no. of subjects | 79 |
| Sex, n (%) | |
| Female | 53 (67.1) |
| Male | 25 (31.6) |
| Unknown | 1 (1.3) |
| Age (y), mean ± SD | 56.2 ± 14.9 |
| Vaccine, n (%) | |
| BNT162b2 (Pfizer-BioNTech) | 38 (48.1) |
| mRNA-1273 (Moderna, Inc) | 34 (43.0) |
| Ad26.COV2.S (Janssen Pharmaceuticals, Inc) | 7 (8.9) |
| Symptom code, n (%) | |
| Psoriasis | 36 (45.6) |
| Condition aggravated | 27 (34.2) |
| Biopsy∗ | 11 (13.9) |
| Guttate psoriasis | 4 (5.1) |
| Autoimmune condition | 1 (1.3) |
| Days to onset, n (%) | |
| 0-7 days | 45 (57.0) |
| 8-27 days | 15 (19.0) |
| ≥28 days | 14 (17.7) |
| Unspecified | 5 (6.3) |
| New-onset psoriasis, n (%) | |
| Total | 22 |
| Guttate | 6 (27.3) |
| Plaque | 16 (72.7) |
| Exacerbation of known disease, n (%) | |
| Total | 57 |
| Guttate | 1 (1.8) |
| Plaque | 56 (98.2) |
∗
Includes “biopsy,” “biopsy skin,” and “biopsy skin abnormal.”